Allogeneic marrow grafts in man using cyclophosphamide.
D000578:Amidines / Q000627:therapeutic use; D001853:Bone Marrow; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000302:isolation & purification; D006086:Graft vs Host Disease / Q000209:etiology; D006087:Graft vs Host Reaction; D006564:Herpesviridae / Q000302:isolation & purification; D006650:Histocompatibility Testing; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications; D007278:Injections, Spinal; D007621:Karyotyping; D007938:Leukemia / Q000628:therapy*; D007945:Leukemia, Lymphoid / Q000628:therapy; D007948:Leukemia, Monocytic, Acute / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D007958:Leukocyte Count; D007959:Lymphocyte Culture Test, Mixed; D008727:Methotrexate / Q000008:administration & dosage; D010647:Phenyl Ethers / Q000627:therapeutic use; D011014:Pneumonia / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D011241:Prednisone / Q000627:therapeutic use; D014181:Transplantation Immunology; D014184:Transplantation, Homologous
D000578:Amidines; D010647:Phenyl Ethers; D003561:Cytarabine; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate